HomeFileCoronary disease

Coronary disease

Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM

In November 2019, during the American Heart Association (AHA) 2019 Scientific Sessions, researchers presented this revolutionary trial...

Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness

Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to...

Virtual ACC 2020 | More data from ISCHEMIA: Women with More Symptoms but Less Ischemia

The ISCHEMIA trial will keep shedding light. The latest data show important differences between men and women...

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses...

16 Years of Superiority of Primary Angioplasty

The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial showed the 30-day superiority of patient transport to a...

Virtual ACC 2020 | “Dangerous” Plaques by CT Effectively Predict Infarction

This post-hoc analysis of the SCOT-HEART shows low-attenuation plaque burden might successfully predict events. A greater number...

Virtual ACC 2020 | Myocardial Ischemia Induced by Sudden Mental Stress

Myocardial ischemia induced by sudden mental stress is associated with bad prognosis, especially in patients with a...

Is There a Relationship between ARBs, ACE 2 Inhibitors and COVID-19?

In the past few days, many doctors appear to have caught wind of somewhat unfounded data. According...